rocky start for alzheimers research
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
Last Updated : GMT 09:40:38
Themuslimchronicle, themuslimchronicle

In 2018

Rocky start for Alzheimer's research

Themuslimchronicle, themuslimchronicle

Themuslimchronicle, themuslimchronicleRocky start for Alzheimer's research

Alzheimer's cure
Paris - Muslimchronicle

The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Within the first three weeks, pharmaceutical giant Pfizer abandoned the costly and frustrating field of dementia drug development, and two promising treatments stumbled in patient trials.

Alzheimer's support groups are putting on a brave face, but the collective disappointment is palpable as the global cost of caring for some 50 million dementia sufferers is set to reach $1 trillion (819 billion euros) this year.

"It's very fair to say that progress is slow," David Reynolds, chief scientific officer at Alzheimer's Research UK, a charity, told AFP.

"Companies have put a lot of time, effort and money in over the last 25 years, and there haven't been any new medicines launched in this area for 16 years now."

Experts say it takes 12–15 years, on average, and more than $2 billion to develop a single drug.

According to the Alzforum website, which gathers data on candidate drugs, fewer than 300 have made it to Phase II drug efficiency trials so far.

Only five have ever been approved to treat symptoms such as memory loss associated with Alzheimer's, first identified more than 100 years ago.

With a clinical trial failure rate of over 99 percent, there is still no licenced drug that slows the condition's progression, or cures it.

Today, about 100 candidate dementia drugs are enrolled in trials, compared to over 1,000 for cancer, according to Reynolds.

One reason is that "pharmaceutical companies ultimately are companies. They are beholden to their investors," he said.

"A return on investment is really: How much time and money do you put into getting a new medicine versus how much money can you make once you've actually got it? In this area, success has been very difficult to come by."

- Mysterious brain -

The stakes are high.

According to the World Health Organization (WHO), some 10 million people per year are diagnosed with dementia, with Alzheimer's disease accounting for about two-thirds of cases.

By 2030, the number of sufferers is projected to reach 82 million globally, and by 2050 some 152 million.

The medical, patient-care, and economic costs are enormous.

A heavy burden falls on family members, the majority of care providers worldwide. Many have to give up their jobs.

Alzheimer's affects mainly older people -- about one in four over-85s is a sufferer. And numbers have soared as lifespans have lengthened thanks to medical advances in other fields.

With cardiovascular disease and cancer the biggest killers in the 1960s and '70s, that is where most of the research money went.

"In dementia, that investment wasn't there. So the amount of knowledge... about the disease is at a much, much earlier stage, and arguably the brain is a much more complicated organ" than the heart, said Reynolds.

To this day, scientists don't know exactly what causes Alzheimer's, leaving drug developers stumped.

On January 6, Pfizer announced an end to its "discovery and early development efforts" for Alzheimer's and Parkinson's dementia drugs.

Two days later, Danish company Lundbeck reported its idalopirdine compound did not "decrease cognitive loss" in patients, and on January 12, biotech firm Axovant announced the end of the road for its offering, intepirdine.

- Slow, but not backwards -

Experts say every failure of a drug reveals something new about Alzheimer's disease, which is thought to be associated with a buildup of protein "plaques", and "tangles" in the brain.

One important recent realisation was that an effective treatment may have to begin long before symptoms appear as protein build-up likely starts decades before disease sets in.

This, in itself, presents a research challenge.

"How do you find these patients?" when they are in middle age and symptom-free, explained French neurology professor Bruno Dubois. "How long do you treat them?"

Drugs in development today are targeting several tracks.

Some use antibodies to mop up proteins in circulation, or enzymes to inhibit their production.

Another experimental approach is vaccination: training the body to produce its own antibodies to attack disease-causing proteins.

"We are not moving backwards," insisted Reynolds.

Yet, he was "by no means certain" that a goal set by the G8 in 2013 to develop a cure or treatment for dementia by 2025 can be met.

"Even knowing the obstacles, we have never been as optimistic as we are today," added James Hendrix, a director at the US-based Alzheimer's Association, one of several non-profit research funders.

"We will not slow down in our fight against this terrible disease," he vowed.

"We are steadfastly committed to both advocating for further increased federal funding for Alzheimer's and dementia research, and increasing our own level of research funding to get us to where we ultimately need to be -- a world without Alzheimer's disease."

themuslimchronicle
themuslimchronicle

GMT 08:57 2018 Tuesday ,23 January

To 'eternal style' of late Alaia

GMT 09:02 2018 Monday ,22 January

Uggs, pigs and tartan

GMT 07:43 2018 Sunday ,21 January

Gardiner announces freelance details

GMT 06:39 2018 Thursday ,18 January

designer Jones quits Louis Vuitton

GMT 08:08 2018 Wednesday ,17 January

Pretty dresses are no longer just

GMT 11:22 2018 Tuesday ,16 January

Lacobella appoints 5th House PR

GMT 08:22 2018 Monday ,15 January

Dolce & Gabbana's royal flush wows

GMT 08:30 2018 Sunday ,14 January

The Dovetail Agency launches events
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

rocky start for alzheimers research rocky start for alzheimers research

 



Themuslimchronicle, themuslimchronicle

GMT 11:34 2017 Tuesday ,26 September

Brady magic rescues Patriots on day of protest

GMT 09:30 2016 Thursday ,03 November

'National Bird' shines light

GMT 10:41 2011 Tuesday ,13 September

\"Turkey needs Arab support\"

GMT 09:02 2018 Monday ,22 January

Uggs, pigs and tartan

GMT 06:39 2018 Thursday ,18 January

designer Jones quits Louis Vuitton

GMT 15:27 2011 Thursday ,14 April

Libya facing humanitarian crisis

GMT 05:51 2011 Thursday ,10 November

IMF : Global economy faces risks

GMT 10:00 2017 Thursday ,06 April

We are trying to re-raise Egyptian cotton value

GMT 10:39 2018 Friday ,05 January

PSG football club lure in fans with escape games

GMT 06:59 2017 Friday ,17 March

Reham Abdel Ghaffor reveals details of her roles

GMT 11:55 2017 Saturday ,18 November

Watchdog fears seizure of more land in West Bank

GMT 08:55 2017 Tuesday ,07 November

Deadly heat from climate change may hit slums hardest

GMT 07:55 2017 Tuesday ,28 March

Wafaa Amer wears Hijab in 'The Flood'

GMT 09:30 2017 Thursday ,06 July

Indian Kashmir tense as key anniversary looms

GMT 16:07 2017 Friday ,03 November

Syria army captures Deir al-Zor city from ISIS

GMT 03:37 2017 Saturday ,08 April

Textbooks spell testing times

GMT 09:41 2017 Monday ,06 February

Herbal medicines could pose hidden risks to health

GMT 16:31 2017 Wednesday ,22 February

Cold Weather and Chance of Light Rain
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
 
 Themuslimchronicle Facebook,themuslimchronicle facebook  Themuslimchronicle Twitter,themuslimchronicle twitter Themuslimchronicle Rss,themuslimchronicle rss  Themuslimchronicle Youtube,themuslimchronicle youtube  Themuslimchronicle Youtube,themuslimchronicle youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©

muslimchronicle muslimchronicle muslimchronicle muslimchronicle
themuslimchronicle themuslimchronicle themuslimchronicle
themuslimchronicle
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
themuslimchronicle, themuslimchronicle, themuslimchronicle